Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
Total Valuation
Cartesian Therapeutics has a market cap or net worth of $267.88M. The enterprise value is $141.57M.
Market Cap$267.88M
Enterprise Value$141.57M
Share Statistics
Cartesian Therapeutics has 25,907,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,907,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cartesian Therapeutics’s return on equity (ROE) is 11.38 and return on invested capital (ROIC) is -10.62%.
Return on Equity (ROE)11.38
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-10.62%
Return on Capital Employed (ROCE)-0.11
Revenue Per Employee589.59K
Profits Per Employee-1.17M
Employee Count66
Asset Turnover0.09
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cartesian Therapeutics is -35.88. Cartesian Therapeutics’s PEG ratio is 0.36.
PE Ratio-35.88
PS Ratio10.69
PB Ratio-408.41
Price to Fair Value-408.41
Price to FCF-84.78
Price to Operating Cash Flow-117.34
PEG Ratio0.36
Income Statement
In the last 12 months, Cartesian Therapeutics had revenue of 38.91M and earned -77.42M in profits. Earnings per share was -0.50.
Revenue38.91M
Gross Profit38.91M
Operating Income-43.90M
Pretax Income-77.14M
Net Income-77.42M
EBITDA-75.99M
Earnings Per Share (EPS)-0.50
Cash Flow
In the last 12 months, operating cash flow was -23.67M and capital expenditures -9.09M, giving a free cash flow of -32.77M billion.
Operating Cash Flow-23.67M
Free Cash Flow-32.77M
Free Cash Flow per Share-1.26
Dividends & Yields
Cartesian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.79
52-Week Price Change-45.31%
50-Day Moving Average15.47
200-Day Moving Average17.39
Relative Strength Index (RSI)42.35
Average Volume (3m)124.85K
Important Dates
Cartesian Therapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Cartesian Therapeutics as a current ratio of 9.43, with Debt / Equity ratio of -205.59%
Current Ratio9.43
Quick Ratio9.43
Debt to Market Cap<0.01
Net Debt to EBITDA2.61
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cartesian Therapeutics has paid 287.00K in taxes.
Income Tax287.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Cartesian Therapeutics EV to EBITDA ratio is -33.95, with an EV/FCF ratio of -78.72.
EV to Sales66.29
EV to EBITDA-33.95
EV to Free Cash Flow-78.72
EV to Operating Cash Flow-108.95
Balance Sheet
Cartesian Therapeutics has $212.61M in cash and marketable securities with $11.86M in debt, giving a net cash position of -$198.63M billion.
Cash & Marketable Securities$212.61M
Total Debt$11.86M
Net Cash-$198.63M
Net Cash Per Share-$7.67
Tangible Book Value Per Share-$0.35
Margins
Gross margin is 99.03%, with operating margin of -112.81%, and net profit margin of -198.97%.
Gross Margin99.03%
Operating Margin-112.81%
Pretax Margin-198.23%
Net Profit Margin-198.97%
EBITDA Margin-195.27%
EBIT Margin-198.23%
Analyst Forecast
The average price target for Cartesian Therapeutics is $37.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.00
Price Target Upside228.60% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast38.82%
EPS Growth Forecast-645.78%